Fiche centre
Research Site
Liverpool — United Kingdom
Essais liés3clinical trials
VilleLiverpoollocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03222973
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BIIB033 (opicinumab) | SEP | Phase 2 | NCT03222973 | AFFINITY — Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | TERMINATED |
| Anifrolumab | Lupus | Phase 3 | NCT05835310 | BLOSSOM — An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | RECRUITING |
| ALXN1720 | Myasthénie | Phase 3 | NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |